ATS View
한국어

DongBang Medical KRX:240550KOSDAQ

동방메디컬 · Korean news coverage and regulatory filings, organized.

한국어
Articles, 24h1
Articles, 7 days6
DART filings, 7 days0
Articles tracked9since Sep 11

In Q2 2026, DongBang Medical reported revenue of ₩33.9bn, up 29.6% year on year, and operating profit of ₩6.4bn. DongBang Medical (동방메디컬) appeared in 6 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 29 with 6 articles. The most common catalyst was clinical & approvals (2).

Filing signals Profit +50% Revenue & profit growth Screener

DongBang Medical quarterly results consolidated, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩33.9bn+29.6%₩6.4bn
margin 18.7%		₩4.0bn
Q1 2026₩31.4bn+13.9%₩6.1bn
margin 19.3%		₩5.3bn
Q4 2025 derived₩29.8bn+6.0%₩5.5bn
margin 18.6%		₩3.5bn
Q3 2025₩30.0bn+13.4%₩4.1bn
margin 13.6%		₩2.8bn
Q2 2025₩26.2bn-0.7%₩3.1bn
margin 12.0%		₩1.9bn
Q1 2025₩27.6bn+13.9%₩4.3bn
margin 15.5%		₩3.2bn
Q4 2024 derived₩28.1bn–₩2.9bn
margin 10.2%		₩1.5bn
Q3 2024₩26.4bn–₩4.7bn
margin 17.9%		₩2.8bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

DongBang Medical top stories 2 weeks, by number of outlets

  1. 1
    동방메디컬, 인체조직은행 설립 허가…ECM 스킨부스터 ‘벨루셀’ 출시 준비
    2 outlets · 2 articlesFirst report Oct 29 10:48 알파경제
  2. 2
    동방메디컬, 조직은행 허가 취득…ECM 스킨부스터 공급망 구축
    1 outlets · 1 articlesFirst report Oct 29 09:36 바이오타임즈Regulatory approval
  3. 3
    동방메디컬, 인체조직은행 설립 허가 획득…“메디컬 에스테틱 사업 확대”
    1 outlets · 1 articlesFirst report Oct 29 15:51 라포르시안Regulatory approval
  4. 4
    동방메디컬, ‘벨루셀’ 출시 채비…인체조직은행 허가로 기반 마련
    1 outlets · 1 articlesFirst report Oct 29 14:03 한스경제
  5. 5
    동방메디컬, ECM 스킨부스터 사업 기반 확보
    1 outlets · 1 articlesFirst report Oct 29 14:13 이데일리

Latest DongBang Medical news Korean headlines